ProCE Banner Activity

IMvigor 210 (Cohort 2): Atezolizumab in Pretreated Metastatic Urothelial Carcinoma

Slideset Download
Conference Coverage
Atezolizumab shows rapid and durable clinical responses and a tolerable safety profile in heavily pretreated patients with metastatic urothelial carcinoma.

Released: June 06, 2016

Expiration: June 05, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals